Analysis of 183 Cases of Adverse Drug Reactions Induced by Atypical Antipsychotropic Drugs

Abstract

Abstract: Objective To learn the occurrence and characteristics of ADR caused by atypical antipsychotic drugs and provide information for rational drug use in clinical practice.Methods 183 ADR reports collected by our hospital from 2013 to 2016 were analyzed using retrospective study method.Results Among 183 cases of ADR reports, most patients were 21 to 40 years old, accounting for 87 cases (47.54%). ADR caused by clozapine and risperidone in the highest proportion accounted for 25.14% and 23.50%. The systems most commonly involved in ADR were nervous system (23.37% ).Serious adverse events such as leucopenia and glucolipid metabolic abnormalities and abnormal electrocardiogram and functional abnormality of the liver usually occurred (accounting for 53.55%).Conclusion Atypical antipsychotic drugs can cause a variety of serious adverse reactions. ADR monitoring and reporting of atypical antipsychotic drugs should be strengthened. The implementation of individualized medication, may avoid or reduce the occurrence of ADR and enhance safety of drug use in patients.

Key words: atypical antipsychotic drug, adverse drug reaction, analysis, rational drug use

CLC Number:

R994.11

ZHANG De-lun, LU Lan, YAO Peng, JIANG Qing-yi. Analysis of 183 Cases of Adverse Drug Reactions Induced by Atypical Antipsychotropic Drugs[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 109-112.

References

[1] 沈渔邨.精神病学[M].5版,北京:人民卫生出版社,2009:876-885.
[2] Thakkar K B,Jain M M,Billa G A,et al.Drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital[J].Clin Diagn Res,2013,7(12):2759–2764.
[3] 胡伟东,黄少平,蔡公平. 3种非典型抗精神病药物不良反应比较与分析[J].中国医药指南, 2011, 9(24):270-273.
[4] Mehta S, Johnson M L, Chen H, et al. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: A propensity-matched retrospective cohort study[J]. J Clin Psychiaty, 2010, 71(6):689-698.
[5] 国家食品药品监督管理总局.关注非典型抗精神病药的严重不良反应药品不良反应信息通报[R].药品不良反应信息通报, 2015, 68:1.
[6] 唐智权,杨思芸.我院774 例药品不良反应报告分析[J].中国药房, 2012, 23(26):2472-2474.
[7] 张德伦,姚鹏,沈宁平,等.某院851例药品不良反应报告分析[J].中国药房, 2013, 24(38):3624-3626.
[8] 宋环霞.我院精神科住院患者药品不良反应报告分析[J].中国药物评价.2016, 33(3):168-171.
[9] 何斌,丁跃庆,王传跃.国内氯氮平引起白细胞减少和粒细胞缺乏文献回顾[J].中国医院用药评价与分析,2003,3(5):307-311.
[10] 周晓亮,何纯正,张昌勇,等.氯氮平诱发白细胞减少与细胞因子的关系[J]. 国际精神病学杂志, 2006, 33(2):126-128.
[11] Patel J K,Buckley P F,Woolson S,et al.Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study[J]. Schizophr Res, 2009, 111(1-3):9-16.
[12] 李洁,姚贵忠,刘丽娟,等.非典型抗精神病药物相关代谢不良反应的系统评价和meta-分析[J].中国心理卫生杂志, 2015, 29(3)：210-216.
[13] Ray W A,Chung C P,Murray K T,et al.Atypical antipsychotic drugs and the risk of sudden cardiac death[J].N Engl J Med, 2009, 360(3): 225- 235.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[3]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[4]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[5]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[6]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[7]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[8]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[9]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[10]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[11]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[12]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[13]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[14]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[15]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.